Efficacy of tralokinumab after failure with upadacitinib and dupilumab in a patient affected by atopic dermatitis

Figures & data

Figure 1. (a) The patient at the end of dupilumab therapy: extensive erythematous involvement of the face and neck. (b) The patient at the end of upadacitinib therapy: erythema and lichenification of the face, neck, and neckline. (c) First follow-up after initiation of tralokinumab: initial reduction in the extent of erythematous lesions and reduction in lichenification at the face.